22nd Century Group (NASDAQ:XXII – Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($3.00) per share and revenue of $8.42 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 7:00 AM ET.
22nd Century Group (NASDAQ:XXII – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($15.60) EPS for the quarter, missing analysts’ consensus estimates of ($6.00) by ($9.60). The company had revenue of $2.86 million for the quarter, compared to analyst estimates of $7.48 million. 22nd Century Group had a negative return on equity of 69.37% and a negative net margin of 27.04%.
22nd Century Group Trading Down 55.3%
Shares of XXII opened at $0.09 on Tuesday. The stock’s 50-day moving average is $1.85 and its two-hundred day moving average is $48.09. The stock has a market cap of $45,614.40, a PE ratio of -0.00 and a beta of 0.72. 22nd Century Group has a 12 month low of $0.09 and a 12 month high of $540.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.61 and a quick ratio of 1.90.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 22nd Century Group in a research note on Monday. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.
Read Our Latest Analysis on 22nd Century Group
22nd Century Group Company Profile
22nd Century Group, Inc is a biotechnology and tobacco company focused on developing products with reduced nicotine content. Its technology is designed to alter the nicotine levels in tobacco plants, with the goal of supporting smoking cessation and reducing exposure to nicotine among adult smokers.
The company’s best-known products include VLN cigarettes, which contain substantially less nicotine than conventional cigarettes. VLN received authorization from the U.S. Food and Drug Administration to be marketed as a modified-risk tobacco product.
Further Reading
- Five stocks we like better than 22nd Century Group
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.
